company background image
CLPT logo

ClearPoint Neuro NasdaqCM:CLPT Stock Report

Last Price

US$5.39

Market Cap

US$145.9m

7D

-13.1%

1Y

-46.0%

Updated

18 Apr, 2024

Data

Company Financials +

ClearPoint Neuro, Inc.

NasdaqCM:CLPT Stock Report

Market Cap: US$145.9m

ClearPoint Neuro, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ClearPoint Neuro
Historical stock prices
Current Share PriceUS$5.39
52 Week HighUS$10.80
52 Week LowUS$4.05
Beta0.92
1 Month Change-22.78%
3 Month Change-28.23%
1 Year Change-45.99%
3 Year Change-71.38%
5 Year Change107.31%
Change since IPO-82.03%

Recent News & Updates

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Recent updates

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Apr 25
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides

Mar 18

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Jan 19
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

Jan 14

ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice

Oct 01

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company

Aug 06

Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Jul 19
Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Clearpoint Neuro (CLPT) Investor Presentation - Slideshow

May 28

Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

May 27
Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

May 13
US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

ClearPoint Neuro partners with D&K Engineering

May 10

ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Path To Profitability

Apr 16
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Path To Profitability

Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 38%?

Mar 21
Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 38%?

This Analyst Just Downgraded Their ClearPoint Neuro, Inc. (NASDAQ:CLPT) EPS Forecasts

Feb 23
This Analyst Just Downgraded Their ClearPoint Neuro, Inc. (NASDAQ:CLPT) EPS Forecasts

Shareholder Returns

CLPTUS Medical EquipmentUS Market
7D-13.1%-4.4%-3.7%
1Y-46.0%-2.8%20.2%

Return vs Industry: CLPT underperformed the US Medical Equipment industry which returned -2.2% over the past year.

Return vs Market: CLPT underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is CLPT's price volatile compared to industry and market?
CLPT volatility
CLPT Average Weekly Movement10.2%
Medical Equipment Industry Average Movement7.4%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: CLPT's share price has been volatile over the past 3 months.

Volatility Over Time: CLPT's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998107Joe Burnettwww.clearpointneuro.com

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

ClearPoint Neuro, Inc. Fundamentals Summary

How do ClearPoint Neuro's earnings and revenue compare to its market cap?
CLPT fundamental statistics
Market capUS$145.90m
Earnings (TTM)-US$22.09m
Revenue (TTM)US$23.96m

6.1x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLPT income statement (TTM)
RevenueUS$23.96m
Cost of RevenueUS$10.34m
Gross ProfitUS$13.61m
Other ExpensesUS$35.70m
Earnings-US$22.09m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.82
Gross Margin56.83%
Net Profit Margin-92.21%
Debt/Equity Ratio47.0%

How did CLPT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.